Large Scale Biology Corporation and Phylogix, Inc. Form Bioprocessing Alliance: Goal to produce therapeutic plant protein to alleviate tissue damage by chemotherapy.

Business Editors/Health & Medical Writers

VACAVILLE, Calif.--(BW HealthWire)--June 10, 2002

Phylogix, Inc. of Scarborough, Maine and Large Scale Biology Corporation (Nasdaq:LSBC) have formed a bioprocessing alliance to develop and manufacture Phylogix, Inc.'s lead therapeutic protein, a native protein in hyacinth seeds called FRIL. The protein represents a novel chemoprotective agent that, in animals, has demonstrated a unique ability to protect normal tissues from the toxic side effects of chemotherapy. LSBC's Owensboro, Kentucky biomanufacturing facility will grow the hyacinth plants in the field and greenhouse, then harvest and purify the active ingredient for projected clinical trials.

At LSBC's Vacaville headquarters, President John D. Fowler called the new alliance "doubly significant, both for the revenue opportunity it represents for LSBC and the commercial validation of our large-scale capabilities to manufacture and purify plant proteins using our proprietary technology."

The Phylogix alliance further validates LSBC's capabilities to produce, extract and purify proteins in plants on a commercial manufacturing scale. LSBC's expertise in agronomics, process development, analytical development, cGMP manufacturing, and regulatory experience provide a comprehensive manufacturing platform for plant therapeutic product development. LSBC recently expanded its Owensboro biomanufacturing facility to enable versatile commercial-scale protein manufacturing, including its internally developed therapeutic vaccine for non-Hodgkin's lymphoma, which will enter Phase II clinical trials later this year.

"We are delighted to be working with LSBC, a world leader in large-scale biomanufacturing of proteins in plants. Entering into an alliance with LSBC to manage the agronomics and manufacture our lead drug candidate brings Phylogix closer to its goal of developing a drug to improve the health and quality of life for chemotherapy patients," said Phylogix President, Jeffrey G. Moore, Ph.D.

About Phylogix, Inc.

Phylogix, Inc. is a privately held biotechnology company in Scarborough, Maine developing a novel class of therapeutics designed to protect and repair tissues damaged by chemotherapy. Its lead compound, the plant lectin called FRIL, has the unique ability to isolate and preserve stem cells. Phylogix seeks to translate these properties into a novel class of plant-based therapeutic agents.

About Large Scale Biology Corporation

Large Scale Biology uses its functional genomics, proteomics, and biomanufacturing technologies to develop and manufacture personalized drugs, vaccines and diagnostics for rapid identification and effective treatment of disease. Corporate offices and the Genomics Division are headquartered in Vacaville, California; the Company's Proteomics Division is located in Germantown, Maryland; and the Company's Bioprocessing Division is located in Owensboro, Kentucky. For more information about Large Scale Biology Corporation, visit the Company's website at www.lsbc.com.

Some statements contained in this release constitute forward-looking statements that involve substantial risks and uncertainties. In some cases, you can identify these statements by words such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," or "continue" and variations of these words or comparable words. In addition, any statements which refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements involve risks, uncertainties and situations that may cause our actual results, level of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this release. For a further list and description of such risks and uncertainties see the reports filed by Large Scale Biology Corporation with the Securities and Exchange Commission, including our reports on Forms 10-K and 10-Q. Except as required by law, we do not undertake to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

LSBC(TM) is a trademark of Large Scale Biology Corporation.